Relypsa, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2007-10-01
- Employees
- 406
- Market Cap
- -
- Website
- https://relypsa.com
Clinical Trials
27
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
- Conditions
- HyperkalemiaResistant Hypertension
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT03071263
- Locations
- 🇺🇸
Investigator Site 1012, Hollywood, Florida, United States
🇺🇸Investigator Site 1023, Miami Lakes, Florida, United States
🇺🇸Investigator Site 1022, Chicago, Illinois, United States
Patiromer With or Without Food for the Treatment of Hyperkalemia
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT02694744
- Locations
- 🇺🇸
Investigator Site 12, Fountain Valley, California, United States
🇺🇸Investigator Site 11, Huntington Beach, California, United States
🇺🇸Investigator Site 38, Palm Springs, California, United States
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02033317
- Locations
- 🇺🇸
Investigator Site, Minneapolis, Minnesota, United States
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
- Conditions
- Hyperkalemia (HK)Chronic Kidney Disease (CKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT01810939
- Locations
- 🇺🇸
Investigator Site 3121, Azusa, California, United States
🇺🇸Investigator Site 3133, Los Angeles, California, United States
🇺🇸Investigator Site 3103, Sacramento, California, United States
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
- Conditions
- Chronic Kidney DiseaseHypertensionHyperkalemia
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Relypsa, Inc.
- Target Recruit Count
- 324
- Registration Number
- NCT01371747
- Locations
- 🇭🇷
Investigator Site 201, Karlovac, Croatia
🇭🇷Investigator Site 207, Osijek, Croatia
🇭🇷Investigator Site 203, Rijeka, Croatia
- Prev
- 1
- 2
- Next